miR-200c inhibits breast cancer proliferation by targeting KRAS

Oncotarget

Volumn 6, Issue 33, 2015, Pages 34968-34978

  Song, Cailu ^a   Liu, Long Zhong ^a   Pei, Xiao Qing ^a   Liu, Xiaoping ^a   Yang, Lu ^a   Ye, Feng ^a   Xie, Xinhua ^a   Chen, Jianping ^b   Tang, Hailin ^a   Xie, Xiaoming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Breast cancer; KRAS; MicroRNA; MiR 200c; Proliferation

Indexed keywords

K RAS PROTEIN; MICRORNA 200C; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; KRAS PROTEIN, HUMAN; MICRORNA; MIRN200 MICRORNA, HUMAN; PROTEIN P21;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER PROGNOSIS; CANCER TISSUE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOUSE; MOUSE MODEL; NONHUMAN; OVERALL SURVIVAL; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; TRANSLATION REGULATION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; AGED; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST TUMOR; CELL PROLIFERATION; DNA MICROARRAY; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; WESTERN BLOTTING;

AGED; ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED BALB C; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS P21(RAS); REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946599841     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5198     Document Type: Article

References (39)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015; 65:5-29.
2. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama. 2006; 295:2492-2502.
3. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13:2329-2334.
4. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, et al. Metastatic breast cancer, version 1: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network: JNCCN. 2012; 10:821-829.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
6. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature reviews Cancer. 2006; 6:857-866.
7. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes & development. 2008; 22:894-907.
8. Kurashige J, Kamohara H, Watanabe M, Hiyoshi Y, Iwatsuki M, Tanaka Y, Kinoshita K, Saito S, Baba Y, Baba H. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Annals of surgical oncology. 2012; 19. 3:S656-664.
9. Du Y, Xu Y, Ding L, Yao H, Yu H, Zhou T, Si J. Downregulation of miR-141 in gastric cancer and its involvement in cell growth. Journal of gastroenterology. 2009; 44:556-561.
10. Ye F, Tang H, Liu Q, Xie X, Wu M, Liu X, Chen B, Xie X. miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. Journal of translational medicine. 2014; 12:17.
11. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15:5060-5072.
12. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, Allgayer H. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Molecular cancer research: MCR. 2010; 8:1207-1216.
13. Chen D, Zhang Y, Wang J, Chen J, Yang C, Cai K, Wang X, Shi F, Dou J. MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117+CD44+ ovarian cancer stem cells by regulating epithelial-mesenchymal transition. Journal of ovarian research. 2013; 6:50.
14. Chen Y, Sun Y, Chen L, Xu X, Zhang X, Wang B, Min L, Liu W. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Molecular medicine reports. 2013; 7:1579-1584.
15. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Molecular cancer therapeutics. 2009; 8:1055-1066.
16. Kopp F, Wagner E, Roidl A. The proto-oncogene KRAS is targeted by miR-200c. Oncotarget. 2014; 5:185-195.
17. Shimizu K, Goldfarb M, Suard Y, Perucho M, Li Y, Kamata T, Feramisco J, Stavnezer E, Fogh J, Wigler MH. Three human transforming genes are related to the viral ras oncogenes. Proceedings of the National Academy of Sciences of the United States of America. 1983; 80:2112-2116.
18. Westaway D, Papkoff J, Moscovici C, Varmus HE. Identification of a provirally activated c-Ha-ras oncogene in an avian nephroblastoma via a novel procedure: cDNA cloning of a chimaeric viral-host transcript. The EMBO journal. 1986; 5:301-309.
19. George DL, Glick B, Trusko S, Freeman N. Enhanced c-Ki-ras expression associated with Friend virus integration in a bone marrow-derived mouse cell line. Proceedings of the National Academy of Sciences of the United States of America. 1986; 83:1651-1655.
20. Gilman AG. G proteins and dual control of adenylate cyclase. Cell. 1984; 36:577-579.
21. Deng M, Tang H, Zhou Y, Zhou M, Xiong W, Zheng Y, Ye Q, Zeng X, Liao Q, Guo X, Li X, Ma J, Li G. miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. Journal of cell science. 2011; 124:2997-3005.
22. Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer research. 2010; 70:6509-6515.
23. Guan JL, Zhong WZ, An SJ, Yang JJ, Su J, Chen ZH, Yan HH, Chen ZY, Huang ZM, Zhang XC, Nie Q, Wu YL. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. Annals of surgical oncology. 2013; 20:1381-1388.
24. Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W, Liu J, Yu J, Chen J. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer research. 2010; 70:6015-6025.
25. Shin KH, Bae SD, Hong HS, Kim RH, Kang MK, Park NH. miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochemical and biophysical research communications. 2011; 404:896-902.
26. Jiang Y, Duan Y, Zhou H. MicroRNA-27a directly targets to inhibit cell proliferation in esophageal squamous cell carcinoma. Oncology letters. 2015; 9:471-477.
27. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer research. 2006; 66:3992-3995.
28. Cerne JZ, Stegel V, Gersak K, Novakovic S. KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study. BMC cancer. 2012; 12:105.
29. Tang H, Deng M, Tang Y, Xie X, Guo J, Kong Y, Ye F, Su Q, Xie X. miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19:5602-5612.
30. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida T, Sato F, Mimata H, Seto M, Moriyama M. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. The Journal of pathology. 2008; 216:418-427.
31. Gao YC, Wu J. MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015; 36:4843-4850.
32. Hubbard PA, Moody CL, Murali R. Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities. Frontiers in physiology. 2014; 5:478.
33. Calvo F, Agudo-Ibanez L, Crespo P. The Ras-ERK pathway: understanding site-specific signaling provides hope of new anti-tumor therapies. BioEssays: news and reviews in molecular, cellular and developmental biology. 2010; 32:412-421.
34. Liu L, Qiu M, Tan G, Liang Z, Qin Y, Chen L, Chen H, Liu J. miR-200c Inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3. Journal of translational medicine. 2014; 12:305.
35. Yu DS, Lv G, Mei XF, Cao Y, Wang YF, Wang YS, Bi YL. MiR-200c regulates ROS-induced apoptosis in murine BV-2 cells by targeting FAP-1. Spinal cord. 2014; doi: 10.1038/sc.2014.185. [Epub ahead of print].
36. Tang H, Wang Z, Liu X, Liu Q, Xu G, Li G, Wu M. LRRC4 inhibits glioma cell growth and invasion through a miR-185-dependent pathway. Current cancer drug targets. 2012; 12:1032-1042.
37. Tang H, Liu P, Yang L, Xie X, Ye F, Wu M, Liu X, Chen B, Zhang L, Xie X. miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer. Molecular cancer therapeutics. 2014; 13:3185-3197.
38. Tang H, Liu X, Wang Z, She X, Zeng X, Deng M, Liao Q, Guo X, Wang R, Li X, Zeng F, Wu M, Li G. Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth. Brain research. 2011; 1390:21-32.
39. Jiang DS, Wang YW, Jiang J, Li SM, Liang SZ, Fang HY. MicroRNA-26a involved in Toll-like receptor 9 mediated lung cancer growth and migration. International journal of molecular medicine. 2014; 34:307-312.